45 related articles for article (PubMed ID: 36422493)
1. Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study.
BirYucel K; Uğraklı M; Sekmek S; Yıldırım N; Gürler F; Yazıcı O; Ozet A; Bal Ö; Araz M; Artaç M; Ozdemir N
Curr Med Res Opin; 2024 Jun; ():1-10. PubMed ID: 38857167
[No Abstract] [Full Text] [Related]
2. Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold.
Schmäche T; Fohgrub J; Klimova A; Laaber K; Drukewitz S; Merboth F; Hennig A; Seidlitz T; Herbst F; Baenke F; Ada AM; Groß T; Wenzel C; Ball CR; Praetorius C; Schmidt T; Ringelband-Schilling B; Koschny R; Stenzinger A; Roeder I; Jaeger D; Zeissig S; Welsch T; Aust D; Glimm H; Folprecht G; Weitz J; Haag GM; Stange DE
Mol Cancer; 2024 Jan; 23(1):10. PubMed ID: 38200602
[TBL] [Abstract][Full Text] [Related]
3. Letter to the editor for the article"efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study".
Wang L; Wu Q; Chi H; Yang G
Int J Surg; 2024 Jun; ():. PubMed ID: 38833345
[No Abstract] [Full Text] [Related]
4. Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience.
Tastekin D; Paksoy N; Dogan I; Ferhatoglu F; Khanmammadov N; Bozbey HU; Karabulut S
J Cancer Res Ther; 2023; 19(2):253-258. PubMed ID: 37006064
[TBL] [Abstract][Full Text] [Related]
5. Modified schedules of DCF chemotherapy for advanced gastric cancer: a systematic review of efficacy and toxicity.
Petrelli F; Tomasello G; Ghidini M; Passalacqua R; Barni S
Anticancer Drugs; 2017 Feb; 28(2):133-141. PubMed ID: 27749286
[TBL] [Abstract][Full Text] [Related]
6. [Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?].
Adenis A; Samalin E; Mazard T; Portales F; Mourregot A; Ychou M
Bull Cancer; 2020 Jan; 107(1):54-60. PubMed ID: 31980145
[TBL] [Abstract][Full Text] [Related]
7. Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Gürler F; Güven DC; Aydemir E; Sütçüoğlu O; İnci BK; Arık Z; Yalçın Ş; Özdemir N; Özet A; Yazıcı O
Turk J Med Sci; 2022 Oct; 52(5):1559-1568. PubMed ID: 36422493
[TBL] [Abstract][Full Text] [Related]
8. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
Inal A; Kaplan MA; Kucukoner M; Isikdogan A
Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
[TBL] [Abstract][Full Text] [Related]
10. Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin and docetaxel (mDCF and mDCX) as a first-line chemotherapy regimen in her 2-negative metastatic gastric cancer patients: A retrospective study.
Demirci NS; Azizy A; Paksoy N; Doğan İ; Karabulut S; Karahan L; Tastekin D
Medicine (Baltimore); 2024 Mar; 103(9):e37259. PubMed ID: 38428877
[TBL] [Abstract][Full Text] [Related]
11. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L
Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
Shah MA; Jhawer M; Ilson DH; Lefkowitz RA; Robinson E; Capanu M; Kelsen DP
J Clin Oncol; 2011 Mar; 29(7):868-74. PubMed ID: 21189380
[TBL] [Abstract][Full Text] [Related]
13. Contribution of chemotherapy to improved prognosis in stage 4 gastric cancer: trend analysis of a regional population-based cancer registry in Japan.
Nakao T; Kaneko R; Tanaka H; Kobayashi S; Omori R; Yano Y; Kamada K; Ikehara T; Sato Y; Igarashi Y
Int J Clin Oncol; 2021 Feb; 26(2):378-386. PubMed ID: 33151441
[TBL] [Abstract][Full Text] [Related]
14. Dose-finding study of modified FLOT (mFLOT) regimen as first-line treatment in Chinese patients with metastatic adenocarcinoma of stomach.
Zhou C; Ma T; Shi M; Xi W; Wu J; Yang C; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2020 Jan; 85(1):113-119. PubMed ID: 31691079
[TBL] [Abstract][Full Text] [Related]
15. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
